Shimadzu's GCMS-TQ8050 NX
The GCMS-TQ8050 NX offers high robustness and the contamination-resistant ion source with the new detector with over five times longer service. With the ultra-high-sensitivity performance of the GCMS-TQ8050 NX, injection volumes can be reduced even further than before.
Shimadzu's GCMS-TQ8050 NX
Drugs containing sartan APIs (active pharmaceutical ingredients), such as valtrasan, candesartan, losartan and olmesartan, are used for treatment of hypertension and heart failure.
Recently US FDA has released finding of probable human carcinogens, N-nitrosodimehyleamine (NDMA), N-nitrosodiethylamine (NDEA) and N—N-methyl-4-aminobutyric acid (NMBA) in sartan drug products and the affected medicines have been recalled. These nitrosamine impurities can form during the production of sartans that contain a functional group known as a tetrazole ring under certain conditions. Additionally , the presence of the impurities in some sartans is possibly due to uses of contaminated equipment or reagents. To detect the presence of the nitrosamine impurities two methods based on headspace GCMS and direct liquid injection are released.
Product Profile:
The GCMS-TQ8050 NX offers high robustness and the contamination-resistant ion source with the new detector with over five times longer service. With the ultra-high-sensitivity performance of the GCMS-TQ8050 NX, injection volumes can be reduced even further than before.
Chromatography GC, GCMS,
LC, HPLC, UHPLC, LCMS, UFM, Spectroscopy, UV-Vis-NIR, FTIR, AAS and EDX, ICPMS, Particle Size, Life Science Lab Instruments, TOC, Material Testing and Measuring Technology.
Contact:
